糖皮质激素作为流感辅助治疗:更新的Cochrane系统评价与Meta分析
该系统评价与Meta分析检索至2018年10月的随机对照试验、准实验设计和观察性队列研究,比较流感患者使用与不使用糖皮质激素。共纳入30项研究,除1项随机对照试验外均为观察性研究。21项观察性研究的死亡率Meta分析提示糖皮质激素治疗与不良结局相关(OR 3.90,95%CI 2.31-6.60;调整HR 1.49,95%CI 1.09-2.02)。7项研究的合并分析显示糖皮质激素组医院获得性感染风险增加(未调整OR 2.74,95%CI 1.51-4.95)。作者结论为流感中糖皮质激素治疗与死亡率升高和医院获得性感染相关,但证据主要涉及高剂量且质量低,适应证混杂是主要担忧。
要点
- 流感患者使用糖皮质激素与死亡率升高相关:21项观察性研究Meta分析OR 3.90(95%CI 2.31-6.60),6项研究调整HR 1.49(95%CI 1.09-2.02)。
- 糖皮质激素组医院获得性感染风险增加:7项研究未调整OR 2.74(95%CI 1.51-4.95)。
- 证据质量低,偏倚风险评估提示可能存在适应证混杂。
- 纳入研究的糖皮质激素剂量较高,大多为甲泼尼龙(或等效剂量)>40 mg/天。
- 剂量与死亡率关系的Meta回归分析未发现关联。
适用人群与场景
- 流感患者(纳入随机对照试验、准实验设计和观察性队列研究,比较糖皮质激素与不使用糖皮质激素)。
研究设计与关键结果
- 系统评价与Meta分析共纳入30项符合条件的研究,除1项随机对照试验外均为观察性研究。
- 21项观察性研究的死亡率Meta分析提示糖皮质激素治疗与不良结局相关:OR 3.90(95%CI 2.31-6.60;15项研究);调整HR 1.49(95%CI 1.09-2.02;6项研究)。
- 7项研究的合并分析显示糖皮质激素组医院获得性感染风险增加:未调整OR 2.74(95%CI 1.51-4.95)。
- 剂量与死亡率关系的Meta回归分析未发现关联,但纳入研究报告的糖皮质激素剂量较高,大多为甲泼尼龙(或等效剂量)>40 mg/天。
- 偏倚风险评估与潜在的适应证混杂一致。
证据类型、等级与局限
- 证据类型:Cochrane系统评价与Meta分析,纳入随机对照试验、准实验设计和观察性队列研究。
- 证据质量:低质量证据。
- 局限:偏倚风险评估提示可能存在适应证混杂。
- 局限:证据主要涉及高剂量糖皮质激素。
- 局限:除1项随机对照试验外均为观察性研究。
对床旁实践的改变
- 作者结论:流感中糖皮质激素治疗与死亡率升高和医院获得性感染相关,但证据主要涉及高剂量且质量低,适应证混杂是主要担忧。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Corticosteroids may be beneficial in sepsis, but uncertainty remains over their effects in severe influenza. This systematic review updates the current evidence regarding corticosteroids in the treatment of influenza and examines the effect of dose on outcome.
DATA SOURCES: Electronic databases (MEDLINE, EMBASE, CINAHL, LILACS, CENTRAL, and Web of Science) and trial registries were searched to October 2018 for randomized controlled trials, quasi-experimental designs, and observational cohort studies reporting corticosteroid versus no corticosteroid treatment in individuals with influenza.
STUDY SELECTION AND DATA EXTRACTION: Two researchers independently assessed studies for inclusion. Risk of bias was assessed using the Cochrane Risk of Bias tool (randomized controlled trials) or Newcastle-Ottawa Scale (observational studies). Where appropriate, we estimated the effect of corticosteroids by random-effects meta-analyses using the generic inverse variance method. Meta-regression analysis was used to assess the association of corticosteroid dose and mortality.
DATA SYNTHESIS: We identified 30 eligible studies, all observational apart from one randomized controlled trial. Twenty-one observational studies were included in the meta-analysis of mortality, which suggested an adverse association with corticosteroid therapy (odds ratio, 3.90; 95% CI, 2.31-6.60; 15 studies; adjusted hazard ratio, 1.49; 95% CI, 1.09-2.02; six studies). Risk of bias assessment was consistent with potential confounding by indication. Pooled analysis of seven studies showed increased odds of hospital-acquired infection in people treated with corticosteroids (unadjusted odds ratio, 2.74; 95% CI, 1.51-4.95). Meta-regression of the effect of dose on mortality did not reveal an association, but reported doses of corticosteroids in included studies were high (mostly > 40 mg methylprednisolone [or equivalent] per day).
CONCLUSIONS: Corticosteroid treatment in influenza is associated with increased mortality and hospital-acquired infection, but the evidence relates mainly to high corticosteroid doses and is of low quality with potential confounding by indication a major concern.
参考来源
- Lansbury LE, Rodrigo C, Leonardi-Bee J, et al. Corticosteroids as Adjunctive Therapy in the Treatment of Influenza: An Updated Cochrane Systematic Review and Meta-analysis. Crit Care Med. 2020. PMID: 31939808. doi:10.1097/CCM.0000000000004093
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。